Correlation between auto-antibodies to survivin and MUC1 variable number Tandem repeats in colorectal cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5557-5562

  Wang, Yu Qian ^a   Zhang, Hai Hong ^a,b   Liu, Chen Lu ^a   Xia, Qiu ^a   Wu, Hui ^a   Yu, Xiang Hui ^a,b   Kong, Wei ^a,b  

^a National Engineering Laboratoty of AIDS Vaccine   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Antibody; Auto; Colorectal cancer; ELISA; MUC1 VNTR; Survivin

Indexed keywords

EID: 84874090882     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5557     Document Type: Article

References (37)

1. Al-Joudi FS, Iskandar ZA (2006). Autoantibodies to survivin in the sera of patients with infiltrating ductal carcinoma of the breast. Med J Malaysia, 61, 302-6.
2. Ambrosini G, Adida C, Altieri DC (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med, 3, 917-21.
3. Apostolopoulos V, McKenzie IF (1994). Cellular mucins: targets for immunotherapy. Crit Rev Immunol, 14, 293-309.
4. Chakravarti A, Noll E, Black PM, et al (2002). Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol, 20, 1063-8.
5. Chen JS, Chen KT, Fan WC, et al (2010). Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer. Clin Chem Lab Med, 48, 719-25.
6. Chung MH, Gupta RK, Hsueh E, et al (2003). Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol, 21, 313-9.
7. Coronella-Wood JA, Hersh EM (2003). Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother, 52, 715-38.
8. Dermime S, Armstrong A, Hawkins RE, Stern PL (2002). Cancer vaccines and immunotherapy. Br Med Bull, 62, 149-62.
9. DiFronzo LA, Gupta RK, Essner R, et al (2002). Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol, 20, 3242-8.
10. Finn OJ, Jerome KR, Henderson RA, et al (1995). MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev, 145, 61-89.
11. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988). A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem, 263, 12820-3.
12. Green MC, Murray JL, Hortobagyi GN (2000). Monoclonal antibody therapy for solid tumors. Cancer Treat Rev, 26, 269-86.
13. Hirasawa Y, Kohno N, Yokoyama A, et al (2000). Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med, 161, 589-94.
14. Hobday TJ (2005). An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer, 5, S11-8.
15. Howat JM, Moore M, Hilton AM, Kimber I (1979). Inhibition of antibody-dependent cellular cytotoxicity by artificial immune complexes and pathological sera. Immunology, 37, 467-75.
16. Hull SR, Bright A, Carraway KL, et al (1989). Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun, 1, 261-7.
17. Ishizaki H, Manuel ER, Song GY, et al (2011). Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother, 60, 99-109.
18. Kameshima H, Tsuruma T, Torigoe T, et al (2011). Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci, 102, 1181-7.
19. Karanikas V, Khalil S, Kerenidi T, Gourgoulianis KI, Germenis AE (2009). Anti-survivin antibody responses in lung cancer. Cancer Lett, 282, 159-66.
20. Lladser A, Parraga M, Quevedo L, et al (2006). Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. Immunobiology, 211, 11-27.
21. Megliorino R, Shi FD, Peng XX, et al (2005). Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev, 29, 241-8.
22. Meyerhard. JA., Mayer RJ (2005). Systemic therapy for colorectal cancer. N Engl J Med, 352, 476-87.
23. Midgley RS, Yanagisawa Y, Kerr DJ (2009). Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol, 6, 108-20.
24. Nakamura H, Hinoda Y, Nakagawa N, et al. (1998). Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol, 33, 354-61.
25. Penland S K, Goldberg RM (2004). Current strategies in previously untreated advanced colorectal cancer. Oncology (Williston Park), 18, 715-22, 727; discussion 727-9.
26. Rohayem J, Diestelkoetter P, Weigle B, et al (2000). Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res, 60, 1815-7.
27. Silk AW, Schoen RE, Potter DM, Finn OJ (2009). Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol, 47, 52-6.
28. Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ, van der Burg SH (2011). Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines, 10, 899-921.
29. Tang CK, Katsara M, Apostolopoulos V (2008). Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines, 7, 963-75.
30. Tang Y, Wang L, Zhang P, et al (2010). Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol, 17, 1903-8.
31. Toubi E, Shoenfeld Y (2007). Protective autoimmunity in cancer (review). Oncol Rep, 17, 245-51.
32. Wan DS (2009). Epidemiologic trend of and strategies for colorectal cancer. Ai Zheng, 28, 897-902.
33. Yagihashi A, Ohmura T, Asanuma K, et al (2005). Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta, 362, 125-30.
34. Yip KW, Shi W, Pintilie M, et al (2006). Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res, 12, 5726-32.
35. Yuan S, Shi C, Ling R, et al (2010). Immunization with two recombinant Bacillus Calmette-Guerin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice. J Cancer Res Clin Oncol, 136, 1359-67.
36. Zhang HH, Zhang SZ, Zhao DH, et al (2008). Construction and expression of human survivin and preparation of its polyclonal antibody. Chem Res Chinese Universities, 24, 767-70.
37. Zhang JY, Casiano CA, Peng XX, et al (2003). Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev, 12, 136-43.